Publications

  1. Janiszewska M*#, Stein S*, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F#, Polyak K#. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer.

JCI Insight, 2021 (in press)

#corresponding authors

*equal contribution

 

  1. Ghiaseddin A, Hoang Minh LB, Janiszewska M, Shin D, Wick W, Mitchell DA, Wen PY, Grossman SA. Adult precision medicine: learning from the past to enhance the future.

Neuro-Oncology Advances, 2020, vdaa145.

 

  1. Hoxa S, Shepard A, Troutman S, Diao H, Doherty JR, Janiszewska M, Witwicki R, Pipkin ME, Ja WW, Kareta MS, Kissil JL. YAP-mediated recruitment of YY1 and EXH2 represses transcription of key cell cycle regulators.

Cancer Research, 2020, 80: 2512-2522.

 

  1. Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta stone of therapy resistance.

Cancer Cell, 2020, 37(4): 471-484.

 

  1. Janiszewska M#, Primi MC, Izard T. Cell adhesion in cancer: Beyond the migration of single cells.

Journal of Biological Chemistry, 2020, 295: 2495-2505.

#corresponding author

 

  1. Janiszewska M. The microcosmos of intratumor heterogeneity: the space-time of cancer evolution.

Oncogene 2020, 39: 2031-2039.

 

  1. Janiszewska M*, Tabassum DP*, Castano Z, Cristea S, Yamamoto K, Kingston NL, Murphy KC, Shu S, Harper NW, Gil Del Alcazar C, Aleckovic M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister S, Polyak K. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments.

Nature Cell Biology 2019, 21(7): 879-888.

*equal contribution

 

  1. Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty M, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K. TRPS1 is a lineage-specific transcriptional dependency in breast cancer.

Cell Reports 2018, 25(5): 1255-1267.

 

  1. Janiszewska M, Polyak K. A confetti trail of tumor evolution.

Nature Cell Biology 2018, 20: 639-641.

 

  1. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the Evolutionary and Ecological Features of Neoplasms.

Nature Reviews Cancer 2017, 17: 605-619.

 

  1. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerrierro JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes.

Cancer Research 2016, 76(22): 6495-6506.

 

  1. Degrauwe N, Suva ML, Janiszewska M, Riggi N, Stamenkovic I. IMPs: an RNA binding protein family that provides a link between stem cell maintenance in normal development and cancer.

Genes and Development 2016, 30: 2459-2474.

 

  1. Degrauwe N, Schlumpf T, Janiszewska M, Martin P, Cauderay A, Provero P, Riggi N, Suva ML, Paro R, Stamenkovic I. The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.

Cell Reports 2016, 15(8): 1634-1647.

 

  1. ShuS, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover D, Ekram MB, Brown J, D’Santos C, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Letai A, Barry W, Carroll JS, Long H, Brown M, Liu SX, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple negative breast cancer.

Nature 2016, 529(7586): 413-417.

 

  1. Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Nature Genetics 2015, 47(10): 1212-1219.

 

  1. Marusyk A, Janiszewska M, Tabassum DP. Determinants of phenotypic intratumor heterogeneity: Integrative approach.

AACR Education book 2015(1): 141-145.

 

  1. Janiszewska M, Polyak K. Clonal evolution in cancer: a tale of twisted twines.

Cell Stem Cell 2015, 16(1): 11-12.

 

  1. Janiszewska M, Beca F, Polyak K. Tumor heterogeneity: the lernaean hydra of oncology?

Oncology (Williston Park). 2014 Sep;28(9).

 

  1. Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clément – Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.

Genes and Development 2012, 1;26(17):1926-44.

  1. De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I. Let-7a is a direct EWS-FLI1 target implicated in Ewing’s sarcoma development.

PLoS One 2011, 6(8): e23592. doi:10.1371/journal.pone.0023592.

 

  1. Janiszewska M, De Vito C, Le Bitoux MA, Fusco C, Stamenkovic I. Transportin regulates nuclear import of CD44.

Journal of Biological Chemistry 2010, 285(40) p. 30548-30557.

 

  1. Nicolo R, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suva D, Tercier S, Joseph JM, Guillou L, Stamenkovic I. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.

Genes and Development 2010, 24(9) p. 916-932.

 

  1. Cironi L, Provero P, Riggi N, Janiszewska M, Suva D, Suva ML, Kindler V, Stamenkovic I. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

PLoS One 2009, 4(11): e7904. doi:10.1371/journal.pone.0007904.

 

  1. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clement V, Stamenkovic I. EZH2 is essential for glioblastoma cancer stem cell maintenance.

Cancer Research 2009, 69(24) p. 9211-9218.

Close Menu